Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TTX 333

Next Previous
Drug Profile

TTX 333

Alternative Names: Dipeptide - AdeTherapeutics; Evitar; Fibrosis prevention dipeptide - AdeTherapeutics; TTX-333

Latest Information Update: 02 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Saskatchewan
  • Developer AdeTherapeutics; Dalton Pharma Services; DSM; Temple Therapeutics
  • Class Antifibrotics; Dipeptides
  • Mechanism of Action Cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Post-surgical adhesions
  • Preclinical Fibrosis

Most Recent Events

  • 02 Feb 2023 Preclinical development for Fibrosis is ongoing in Netherlands (Temple therapeutics pipeline; January 2023)
  • 05 Jun 2018 TTX 333 is still in phase II trials for Post surgical adhesions (Prevention) in Canada (Temple Therapeutics pipeline, May 2018)
  • 23 Apr 2013 TTX 333 is available for licensing. http://www.adetherapeutics.com
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top